198 related articles for article (PubMed ID: 25426562)
1. PAK6 increase chemoresistance and is a prognostic marker for stage II and III colon cancer patients undergoing 5-FU based chemotherapy.
Chen J; Lu H; Yan D; Cui F; Wang X; Yu F; Xue Y; Feng X; Wang J; Wang X; Jiang T; Zhang M; Zhao S; Yu Y; Tang H; Peng Z
Oncotarget; 2015 Jan; 6(1):355-67. PubMed ID: 25426562
[TBL] [Abstract][Full Text] [Related]
2. Prognostic relevance of Src activation in stage II-III colon cancer.
Martínez-Pérez J; Lopez-Calderero I; Saez C; Benavent M; Limon ML; Gonzalez-Exposito R; Soldevilla B; Riesco-Martínez MC; Salamanca J; Carnero A; Garcia-Carbonero R
Hum Pathol; 2017 Sep; 67():119-125. PubMed ID: 28601656
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and Predictive Value of p21-activated Kinase 6 Associated Support Vector Machine Classifier in Gastric Cancer Treated by 5-fluorouracil/Oxaliplatin Chemotherapy.
Jiang Y; Liu W; Li T; Hu Y; Chen S; Xi S; Wen Y; Huang L; Zhao L; Xiao C; Huang X; Han Z; Liu H; Qi X; Yang Y; Yu J; Cai S; Li G
EBioMedicine; 2017 Aug; 22():78-88. PubMed ID: 28687498
[TBL] [Abstract][Full Text] [Related]
4. Lysosomal acid phosphatase 2 is an unfavorable prognostic factor but is associated with better survival in stage II colorectal cancer patients receiving chemotherapy.
Lee YC; Su CY; Lin YF; Lin CM; Fang CY; Lin YK; Hsiao M; Chen CL
Oncotarget; 2017 Feb; 8(7):12120-12132. PubMed ID: 28076332
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of p21-activated kinase 6 expression in patients with clear cell renal cell carcinoma.
Liu W; Liu H; Liu Y; Xu L; Zhang W; Zhu Y; Xu J; Gu J
Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S575-83. PubMed ID: 24715215
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of oral tegafur-uracil as maintenance therapy following intravenous 5-fluorouracil chemotherapy in stage III colon cancer.
Hong KD; Lee SI; Moon HY
Hepatogastroenterology; 2012; 59(113):104-7. PubMed ID: 22251527
[TBL] [Abstract][Full Text] [Related]
8. Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy.
Zhao S; Jiang T; Tang H; Cui F; Liu C; Guo F; Lu H; Xue Y; Jiang W; Peng Z; Yan D
J Gastroenterol Hepatol; 2015 Apr; 30(4):680-8. PubMed ID: 25238407
[TBL] [Abstract][Full Text] [Related]
9. High-level expression of P21-Cdc/Rac-activated kinase 7 is closely related to metastatic potential and poor prognosis of colon carcinoma.
Li C; Chen J; Wang Y; Song G; Xiao C; Yan D; Zhong L; Sun X; Wang X; Yu F; Yu Y; Tang H; Peng Z
Oncotarget; 2016 Jul; 7(29):46042-46055. PubMed ID: 27323857
[TBL] [Abstract][Full Text] [Related]
10. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM
J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028
[TBL] [Abstract][Full Text] [Related]
11. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.
O'Connell MJ; Campbell ME; Goldberg RM; Grothey A; Seitz JF; Benedetti JK; André T; Haller DG; Sargent DJ
J Clin Oncol; 2008 May; 26(14):2336-41. PubMed ID: 18467725
[TBL] [Abstract][Full Text] [Related]
12. The c-MYC-ABCB5 axis plays a pivotal role in 5-fluorouracil resistance in human colon cancer cells.
Kugimiya N; Nishimoto A; Hosoyama T; Ueno K; Enoki T; Li TS; Hamano K
J Cell Mol Med; 2015 Jul; 19(7):1569-81. PubMed ID: 25689483
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of p21-activated kinase 6 (PAK6) increases radiosensitivity of prostate cancer cells.
Zhang M; Siedow M; Saia G; Chakravarti A
Prostate; 2010 Jun; 70(8):807-16. PubMed ID: 20054820
[TBL] [Abstract][Full Text] [Related]
14. Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer.
de Vos tot Nederveen Cappel WH; Meulenbeld HJ; Kleibeuker JH; Nagengast FM; Menko FH; Griffioen G; Cats A; Morreau H; Gelderblom H; Vasen HF
Int J Cancer; 2004 Apr; 109(3):468-71. PubMed ID: 14961589
[TBL] [Abstract][Full Text] [Related]
15. Methylation status at HYAL2 predicts overall and progression-free survival of colon cancer patients under 5-FU chemotherapy.
Pfütze K; Benner A; Hoffmeister M; Jansen L; Yang R; Bläker H; Herpel E; Ulrich A; Ulrich CM; Chang-Claude J; Brenner H; Burwinkel B
Genomics; 2015 Dec; 106(6):348-54. PubMed ID: 26453961
[TBL] [Abstract][Full Text] [Related]
16. FANCJ expression predicts the response to 5-fluorouracil-based chemotherapy in MLH1-proficient colorectal cancer.
Nakanishi R; Kitao H; Fujinaka Y; Yamashita N; Iimori M; Tokunaga E; Yamashita N; Morita M; Kakeji Y; Maehara Y
Ann Surg Oncol; 2012 Oct; 19(11):3627-35. PubMed ID: 22526901
[TBL] [Abstract][Full Text] [Related]
17. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.
Dahl O; Fluge Ø; Carlsen E; Wiig JN; Myrvold HE; Vonen B; Podhorny N; Bjerkeset O; Eide TJ; Halvorsen TB; Tveit KM;
Acta Oncol; 2009; 48(3):368-76. PubMed ID: 19242829
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.
Okada K; Fujiwara Y; Takahashi T; Nakamura Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
Ann Surg Oncol; 2013 Mar; 20(3):1035-43. PubMed ID: 23054116
[TBL] [Abstract][Full Text] [Related]
19. A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer.
Öhrling K; Karlberg M; Edler D; Hallström M; Ragnhammar P
Clin Colorectal Cancer; 2013 Jun; 12(2):128-35. PubMed ID: 23276521
[TBL] [Abstract][Full Text] [Related]
20. Karyopherin alpha 2 is a novel prognostic marker and a potential therapeutic target for colon cancer.
Zhang Y; Zhang M; Yu F; Lu S; Sun H; Tang H; Peng Z
J Exp Clin Cancer Res; 2015 Dec; 34():145. PubMed ID: 26626145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
